Market: NMS |
Currency: USD
Address: 822 A1A North
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
📈 Cadrenal Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$35.00
-
Upside/Downside from Analyst Target:
382.09%
-
Broker Call:
2
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Cadrenal Therapeutics, Inc.
| Date | Reported EPS |
|---|
| 2026-03-31 | -1.41 |
| 2025-11-10 | -1.31 |
| 2025-08-11 | -1.87 |
| 2025-05-08 | -2.09 |
| 2025-03-13 | -8.73 |
| 2024-11-07 | -2.18 |
| 2024-08-07 | -2.25 |
| 2024-05-09 | -1.5 |
| 2024-03-11 | -1.87 |
📰 Related News & Research
🔍 View more Reports
